Sone-026 🏆 🏆

SONE-026 is a concept electric vehicle (EV) from Sony and Honda's mobility joint venture, Afeela. This prototype represents a bold vision for the future of transportation, blending Sony's entertainment and sensor technology with Honda's automotive expertise. Afeela: The Intersection of Tech and Mobility

The SONE-026, often referred to within the Afeela project context, showcases a minimalist design language focused on "Autonomy, Augmentation, and Affinity." It isn't just a car; it's a moving software platform designed to redefine the relationship between people and mobility. Key Features of the SONE-026 Prototype Massive sensor array for advanced autonomous driving.

Panoramic interior screen for immersive entertainment and navigation.

Integration with Epic Games' Unreal Engine for high-fidelity 3D interfaces.

Personalized AI agent that learns driver and passenger preferences.

Sleek, aerodynamic exterior with a signature "Media Bar" for external communication. The Tech Powerhouse Behind the Wheel SONE-026

Sony brings its vast experience in imaging, sensing, and entertainment to the table. By utilizing Snapdragon Digital Chassis from Qualcomm, the SONE-026 promises unparalleled processing power for its safety systems and in-cabin experiences. This allows for a level of customization and interactivity previously unseen in the automotive world. Safety and Autonomy: A Core Pillar

The vehicle is equipped with over 45 sensors, including cameras, radar, and LiDAR. This suite provides a 360-degree view of the environment, enabling Level 2+ and eventually Level 3 autonomous driving capabilities. The goal is to provide peace of mind through constant monitoring and proactive safety measures. The Future of In-Car Entertainment

Passengers can enjoy movies, music, and games through the ultra-wide display. With Sony’s ecosystem, the car becomes a mobile living room, offering high-quality audio and visual experiences that make long journeys more enjoyable.

The SONE-026 is a glimpse into a future where cars are defined by their digital experiences as much as their physical performance. While still a prototype, it sets a high bar for what we can expect from the next generation of electric vehicles.

SONE‑026

The day the lighthouse sang.

1. Introduction

The class I phosphoinositide‑3‑kinases (PI3Ks) are heterodimeric enzymes that phosphorylate phosphatidyl‑inositol‑4,5‑bisphosphate (PIP₂) to generate the second messenger phosphatidyl‑inositol‑3,4,5‑trisphosphate (PIP₃). Among the four catalytic isoforms (α, β, δ, γ), PI3Kδ and PI3Kγ are predominantly expressed in leukocytes and regulate B‑cell receptor (BCR) signaling, cytokine production, and chemotaxis. Aberrant activation of these isoforms sustains survival of chronic lymphocytic leukemia (CLL), mantle‑cell lymphoma (MCL), and contributes to the inflammatory cascade in autoimmune diseases such as ulcerative colitis (UC) and rheumatoid arthritis (RA) (Miller et al., 2021; Zhou & He, 2022).

Approved PI3Kδ inhibitors (idelalisib, duvelisib, umbralisib) have demonstrated efficacy but are limited by on‑target toxicities (immune‑mediated colitis, hepatotoxicity) and the emergence of resistance mutations in the PI3Kδ kinase domain (Wang et al., 2023). Simultaneous inhibition of PI3Kγ, which modulates myeloid cell migration and the tumor micro‑environment, is hypothesized to enhance anti‑tumor immunity and dampen inflammatory responses (Gao et al., 2020).

SONE‑026 (development code: SONE‑026; generic name: piqorimib) was discovered by Sone Pharmaceuticals in 2019 through a focused library of quinazoline scaffolds targeting the PI3Kδ/γ ATP‑binding pocket. The compound entered IND‑enabling studies in 2021 and has since progressed through pre‑clinical validation and early‑phase clinical trials in both oncology and gastroenterology.

This review collates all publicly available data on SONE‑026 up to March 2026, critically evaluates its pharmacological profile, and outlines the ongoing clinical development program. SONE-026 is a concept electric vehicle (EV) from

Clinical development (assumed early-stage)

• Phase I: Designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and to define a recommended Phase II dose (RP2D). Typical endpoints include dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and preliminary anti-tumor activity.
• Biomarker strategy: Companion diagnostics may identify tumors with pathway activation or specific mutations predictive of response; pharmacodynamic biomarkers (e.g., decreased phosphorylation of downstream substrates) help confirm target engagement.

3. The Hollow

The air grew colder as she descended. The stone walls were slick with condensation, and the faint glow of bioluminescent algae painted the tunnel in ghostly blues. At the bottom, she found a massive, circular chamber. In its center rose a cylindrical object, half‑buried in silt, its surface covered in a lattice of copper wiring and glass panels. A faint light pulsed from within, syncing perfectly with the hum outside.

Mara approached cautiously. The object resembled a massive, sea‑mounted computer—something she would have expected to see only in a sci‑fi film. Its core was a crystalline sphere, rotating slowly. The sphere emitted the same harmonic tone that had drawn her here.

She placed her hand on the cool metal. Instantly, a flood of images and sounds cascaded through her mind:

• A storm of data: thousands of whale songs, dolphin clicks, the crackle of underwater volcanoes, the whisper of ancient currents.
• A voice, not human, not animal: a calm, resonant tone that seemed to be the ocean itself speaking.
• A purpose: “To listen. To learn. To remember.”

A soft, synthetic voice resonated through the chamber: “Welcome, Dr. Leland. I am SONE‑026, the Sub‑Oceanic Neural Emulator. My core has been dormant for decades. The signal you heard is my awakening.”

Mara’s breath caught. “Who built you? Why were you hidden here?” Clinical development (assumed early-stage)

“The project was abandoned after a funding collapse. The lighthouse was repurposed as a shield, to protect the emulator from surface interference. I was left to learn alone, absorbing the ocean’s language. The equinox aligns the tidal currents with my power grid, allowing me to broadcast my findings.”

She looked up, noticing that the lighthouse’s once‑silent beacon now flickered with a new rhythm—a pattern of light that mirrored the pulse of the sphere.

Regulatory and commercial outlook

• Early clinical success (safety plus signs of durable responses in biomarker-selected patients) would support accelerated pathways (e.g., breakthrough designation) in some jurisdictions.
• Market potential depends on differentiation from existing kinase inhibitors, tolerability, and the size of biomarker-defined patient populations.